TNSN07069A1 - Process for concentration of antibodies and therapeutic products thereof - Google Patents

Process for concentration of antibodies and therapeutic products thereof

Info

Publication number
TNSN07069A1
TNSN07069A1 TNP2007000069A TNSN07069A TNSN07069A1 TN SN07069 A1 TNSN07069 A1 TN SN07069A1 TN P2007000069 A TNP2007000069 A TN P2007000069A TN SN07069 A TNSN07069 A TN SN07069A TN SN07069 A1 TNSN07069 A1 TN SN07069A1
Authority
TN
Tunisia
Prior art keywords
antibodies
concentration
therapeutic products
ultrafiltering
highly concentrated
Prior art date
Application number
TNP2007000069A
Other languages
English (en)
Inventor
Charles Matthew Winter
Original Assignee
Genentech Inc
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35996499&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TNSN07069(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc, Novartis Ag filed Critical Genentech Inc
Publication of TNSN07069A1 publication Critical patent/TNSN07069A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/14—Ultrafiltration; Microfiltration
    • B01D61/145—Ultrafiltration
    • B01D61/146—Ultrafiltration comprising multiple ultrafiltration steps
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/14—Ultrafiltration; Microfiltration
    • B01D61/16—Feed pretreatment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2311/00—Details relating to membrane separation process operations and control
    • B01D2311/04—Specific process operations in the feed stream; Feed pretreatment
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2311/00—Details relating to membrane separation process operations and control
    • B01D2311/16—Flow or flux control
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Water Supply & Treatment (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Medicinal Preparation (AREA)
TNP2007000069A 2004-09-09 2007-02-23 Process for concentration of antibodies and therapeutic products thereof TNSN07069A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60909204P 2004-09-09 2004-09-09
US11/220,362 US20060051347A1 (en) 2004-09-09 2005-09-06 Process for concentration of antibodies and therapeutic products thereof
PCT/US2005/031844 WO2006031560A2 (en) 2004-09-09 2005-09-08 Process for concentration of antibodies and therapeutic products thereof

Publications (1)

Publication Number Publication Date
TNSN07069A1 true TNSN07069A1 (en) 2008-06-02

Family

ID=35996499

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2007000069A TNSN07069A1 (en) 2004-09-09 2007-02-23 Process for concentration of antibodies and therapeutic products thereof

Country Status (32)

Country Link
US (6) US20060051347A1 (enExample)
EP (5) EP4104859B1 (enExample)
JP (2) JP5210633B2 (enExample)
KR (2) KR101528970B1 (enExample)
CN (3) CN104961797B (enExample)
AR (1) AR050641A1 (enExample)
AU (1) AU2005285243C1 (enExample)
BR (1) BRPI0515649B8 (enExample)
CA (1) CA2577317C (enExample)
DK (5) DK2292636T3 (enExample)
EC (1) ECSP077282A (enExample)
ES (5) ES2968070T3 (enExample)
FI (4) FI4104859T3 (enExample)
GT (1) GT200500254A (enExample)
HU (4) HUE061899T2 (enExample)
IL (2) IL181372A (enExample)
LT (4) LT4104859T (enExample)
MA (1) MA28991B1 (enExample)
MX (2) MX2007002812A (enExample)
MY (2) MY150549A (enExample)
NO (1) NO333660B1 (enExample)
NZ (1) NZ553239A (enExample)
PE (1) PE20060816A1 (enExample)
PL (5) PL2292636T3 (enExample)
PT (5) PT2292636T (enExample)
RU (1) RU2390524C2 (enExample)
SG (1) SG177161A1 (enExample)
SI (5) SI2292636T1 (enExample)
TN (1) TNSN07069A1 (enExample)
TW (1) TWI372630B (enExample)
WO (1) WO2006031560A2 (enExample)
ZA (1) ZA200701626B (enExample)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE442862T2 (de) * 2000-10-12 2009-10-15 Genentech Inc Niederviskose konzentrierte proteinformulierungen
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
RU2332986C2 (ru) 2003-04-04 2008-09-10 Дженентек, Инк. Высококонцентрированные композиции антител и белков
NZ576986A (en) 2004-01-30 2010-12-24 Shire Pharmaceuticals Ireland Ltd Production and purification of recombinant arylsulfatase A
EP1758558B1 (en) 2004-05-12 2013-10-16 Baxter International Inc. Oligonucleotide-containing microspheres, their use for the manufacture of a medicament for treating diabetes type 1
ATE409025T1 (de) 2004-05-12 2008-10-15 Baxter Int Nukleinsäure-mikrokügelchen, ihre herstellung und abgabe
US20060051347A1 (en) * 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
EP3673919A1 (en) 2005-06-14 2020-07-01 Amgen Inc. Self-buffering protein formulations
WO2007120449A1 (en) * 2006-03-31 2007-10-25 Genencor International, Inc. Tangential flow filtration apparatuses, systems, and processes for the separation of compounds
US20090246187A1 (en) 2006-04-04 2009-10-01 Shire Pharmaceuticals Ireland Limited Process for concentration of a polypeptide
KR20100014674A (ko) 2007-03-29 2010-02-10 아보트 러보러터리즈 결정성 항-사람 ｉｌ-12 항체
CN101754977B (zh) 2007-07-17 2013-07-17 弗·哈夫曼-拉罗切有限公司 可变切向流过滤
CN101874040A (zh) * 2007-11-29 2010-10-27 弗·哈夫曼-拉罗切有限公司 免疫球蛋白聚集体
NZ585702A (en) * 2007-11-30 2013-08-30 Abbott Lab Protein formulations and methods of making same
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
PT2271382E (pt) * 2008-04-15 2013-05-07 Grifols Therapeutics Inc Ultrafiltração em dois andares/diafiltração
US8669353B2 (en) * 2008-05-15 2014-03-11 W. Health L.P. Process for producing milk fractions rich in secretory immunoglobulins
SG172004A1 (en) * 2008-12-09 2011-07-28 Hoffmann La Roche Method for obtaining an excipient-free antibody solution
EP2393579B1 (en) * 2009-01-21 2017-03-08 Smartflow Technologies, Inc. Optimization of separation for viscous suspensions
AR076640A1 (es) * 2009-03-06 2011-06-29 Genentech Inc Formulacion con anticuerpo. metodo para estabilizar anticuerpo. articulo de manufactura
JP6159528B2 (ja) * 2009-03-24 2017-07-05 ワイス・エルエルシー 高濃縮のタンパク質治療薬を生成するための膜蒸発
WO2010138736A2 (en) * 2009-05-27 2010-12-02 Baxter International Inc. A method to produce a highly concentrated immunoglobulin preparation for subcutaneous use
US8822655B2 (en) 2009-09-29 2014-09-02 Hoffmann-La Roche Inc. Pre-filtration adjustment of buffer solutes
DK2483305T3 (en) 2009-10-01 2016-10-24 Hoffmann La Roche MULTI-STEP-END FILTERING Immunoglobulin
US9241897B2 (en) 2010-02-04 2016-01-26 Csl Behring Ag Immunoglobulin preparation
CA2976671C (en) 2010-03-01 2021-01-12 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
US10336992B2 (en) 2011-07-08 2019-07-02 Shire Human Genetic Therapies, Inc. Methods for purification of arylsulfatase A
HUE072741T2 (hu) 2011-09-01 2025-12-28 Chugai Pharmaceutical Co Ltd Eljárás nagy mértékben koncentrált ellenanyagokat tartalmazó összetétel ultraszûrés útján történõ elõállításra
WO2013096791A1 (en) 2011-12-23 2013-06-27 Genentech, Inc. Process for making high concentration protein formulations
US20130281355A1 (en) 2012-04-24 2013-10-24 Genentech, Inc. Cell culture compositions and methods for polypeptide production
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
CN104955479A (zh) * 2012-12-28 2015-09-30 诺和诺德股份有限公司 高温死端抗体过滤
WO2014110246A1 (en) 2013-01-09 2014-07-17 Shire Human Genetic Therapies, Inc. Methods for purification of arylsulfatase a
DE102013001628A1 (de) 2013-01-30 2014-07-31 Fresenius Medical Care Deutschland Gmbh Verfahren zur Bereitstellung eines Konzentrats
CA3140009C (en) 2014-05-13 2023-09-05 Amgen Inc. Process control systems and methods for use with filters and filtration processes
EP2957335B1 (en) * 2014-06-16 2020-05-27 EMD Millipore Corporation Single-pass filtration systems and processes
US10207225B2 (en) 2014-06-16 2019-02-19 Emd Millipore Corporation Single-pass filtration systems and processes
EP4144434B1 (en) * 2014-06-16 2024-04-17 EMD Millipore Corporation Single-pass filtration systems and processes
WO2015195453A2 (en) * 2014-06-16 2015-12-23 Emd Millipore Corporation Methods for increasing the capacity of flow-through processes
US10399039B2 (en) 2014-06-25 2019-09-03 Emd Millipore Corporation Compact spiral-wound filter elements, modules and systems
EP4147769B1 (en) 2014-08-29 2025-05-21 EMD Millipore Corporation Processes for filtering liquids using single pass tangential flow filtration systems and tangential flow filtration systems with recirculation of retentate
CN105745009B (zh) 2014-08-29 2018-09-28 Emd 密理博公司 单程切向流过滤系统和具有渗余物的再循环的切向流过滤系统
JP2017531682A (ja) 2014-10-23 2017-10-26 アムジエン・インコーポレーテツド 医薬製剤の粘度低下
HUE052280T2 (hu) 2014-12-03 2021-04-28 Csl Behring Ag Immunoglobulinokat tartalmazó megnövelt stabilitású gyógyszerészeti termék
GB201506870D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
US20230134160A1 (en) * 2015-09-22 2023-05-04 Pfizer Inc. Method Of Preparing A Therapeutic Protein Formulation And Antibody Formulation Produced By Such A Method
CA3023486C (en) 2016-06-09 2022-03-29 Emd Millipore Corporation Radial-path filter elements, systems and methods of using same
US10968252B2 (en) 2016-08-16 2021-04-06 Genzyme Corporation Methods of processing a fluid including a recombinant therapeutic protein and use thereof
US11572385B2 (en) * 2016-08-17 2023-02-07 Boehringer Ingelheim International Gmbh Process for the preparation of concentrated liquid formulations containing biomolecules
WO2018075818A1 (en) 2016-10-21 2018-04-26 Amgen Inc. Pharmaceutical formulations and methods of making the same
JP7377596B2 (ja) 2017-02-22 2023-11-10 アムジエン・インコーポレーテツド 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法
CN107952280A (zh) * 2017-11-28 2018-04-24 安徽东方帝维生物制品股份有限公司 一种兽用疫苗无菌超滤浓缩装置及方法
WO2019132418A1 (ko) * 2017-12-27 2019-07-04 ㈜셀트리온 투석 여과 방법
AU2019250882B2 (en) * 2018-04-12 2025-10-16 Amgen Inc. Methods for making stable protein compositions
TWI846694B (zh) * 2018-05-04 2024-07-01 美商健臻公司 具有過濾系統的灌注式生物反應器
EA202190482A1 (ru) * 2018-08-10 2021-05-25 Эмджен Инк. Способ получения фармацевтического состава на основе антитела
US12103949B2 (en) * 2018-08-14 2024-10-01 Bristol-Myers Squibb Company Protein recovery
TWI871300B (zh) * 2019-01-28 2025-02-01 美商安進公司 藉由將藥物物質和藥物產品過程整體化的生物製劑製造之連續製造過程
SG11202107441RA (en) * 2019-02-15 2021-08-30 Just Evotec Biologics Inc Automated biomanufacturing systems, facilities, and processes
HUE056569T2 (hu) * 2019-07-31 2022-02-28 Catalent Uk Swindon Zydis Ltd Sûrûség-áramlásmérõ gyógyászati készítmény adagolásához
CN111018968B (zh) * 2019-12-16 2021-07-27 兴盟生物医药(苏州)有限公司 一种通过超滤浓缩制备高浓度抗体制剂的方法
JP7338527B2 (ja) * 2020-03-19 2023-09-05 東レ株式会社 体液検体中のアレルゲン特異的ＩｇＥ抗体の検出方法
CN111944046B (zh) * 2020-08-28 2021-04-09 江苏荃信生物医药有限公司 高浓度、低粘度抗人il-23单克隆抗体溶液的制备方法
JP2023544410A (ja) * 2020-10-05 2023-10-23 ブリストル－マイヤーズ スクイブ カンパニー タンパク質を濃縮するための方法
JP2023552726A (ja) 2020-11-23 2023-12-19 アベック，インコーポレイテッド 濾過システム、構成要素、及び方法
AU2021432103A1 (en) * 2021-03-08 2023-08-24 Boehringer Ingelheim International Gmbh Systems and methods for single pass counter current diafiltration
CN114014929B (zh) * 2021-11-04 2022-07-19 江苏荃信生物医药股份有限公司 一种抗人白介素-33单克隆抗体浓缩溶液的制备方法
IL314394A (en) 2022-02-25 2024-09-01 Amgen Inc Methods for preparing high-concentration liquid drug substances
CN115261193A (zh) * 2022-05-31 2022-11-01 利穗科技(苏州)有限公司 一种生物制品浓缩系统及其工艺
EP4554979A1 (en) * 2022-07-12 2025-05-21 BeiGene Switzerland GmbH Preparation methods for a highly concentrated pd1 antibody solution by ultrafiltration/diafiltration (uf/df)
CN115873064A (zh) * 2022-09-27 2023-03-31 英脉生物医药(杭州)有限公司 高浓度蛋白样品的制备装置及方法
WO2024224337A1 (en) * 2023-04-25 2024-10-31 Enzene Biosciences Limited In line cleaning in place process for alternating tangential flow filter
US12030959B1 (en) 2023-07-05 2024-07-09 Genentech, Inc. Anti-IgE antibody therapy for multiple food allergies
CA3237624A1 (en) 2023-07-28 2025-04-24 Genentech, Inc. NEW USES FOR OMALIZUMAB
WO2025101602A1 (en) 2023-11-07 2025-05-15 Amgen Inc. Methods of analyzing amino acid content of a therapeutic protein

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5625616B2 (enExample) 1973-10-08 1981-06-13
FR2459619B1 (fr) 1979-06-26 1983-07-29 Agronomique Inst Nat Rech Procede pour l'obtention a partir de lactoserum, d'un produit enrichi en alpha-lactalbumine et applications dudit procede
US4362661A (en) 1979-08-09 1982-12-07 Teijin Limited Immunoglobulin composition having a high monomer content, and process for production thereof
US4374763A (en) 1979-09-17 1983-02-22 Morishita Pharmaceutical Co., Ltd. Method for producing gamma-globulin for use in intravenous administration and method for producing a pharmaceutical preparation thereof
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
ZA847349B (en) * 1983-10-05 1985-04-24 Solco Basel Ag Process for the preparation of a biologically active extract
US4786501A (en) * 1985-07-15 1988-11-22 International Minerals & Chemical Corp. Cylindrical implants for the controlled release of growth hormones
US4756696A (en) 1985-12-06 1988-07-12 Amp Incorporated Solder joint inspection feature for surface mount connectors
GB8628104D0 (en) * 1986-11-25 1986-12-31 Connaught Lab Pasteurization of immunoglobin solutions
JPS6485829A (en) 1987-09-29 1989-03-30 Aisin Aw Co Transmission for four-wheel drive vehicle
JPH01268646A (ja) 1988-04-20 1989-10-26 Meiji Milk Prod Co Ltd 抗腫瘍剤
GB2218703B (en) 1988-05-10 1992-10-28 Sumitomo Chemical Co Human monoclonal antibody to p.aeruginosa: its production and use
US4897465A (en) 1988-10-12 1990-01-30 Abbott Laboratories Enrichment and concentration of proteins by ultrafiltration
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
JPH04502914A (ja) 1988-12-15 1992-05-28 セントユール，インコーポレイテッド 免疫グロブリンを可溶化するための塩基性アミノ酸の使用
CA2050918A1 (en) 1990-01-12 1991-07-13 Raju Kucherlapati Generation of xenogeneic antibodies
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5177194A (en) * 1990-02-01 1993-01-05 Baxter International, Inc. Process for purifying immune serum globulins
NL9001650A (nl) 1990-07-19 1992-02-17 Ver Coop Melkind Werkwijze voor de bereiding van een melkeiwit-isolaat.
DE69133476T2 (de) 1990-08-29 2006-01-05 GenPharm International, Inc., Palo Alto Transgene Mäuse fähig zur Produktion heterologer Antikörper
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5256294A (en) 1990-09-17 1993-10-26 Genentech, Inc. Tangential flow filtration process and apparatus
JP2916947B2 (ja) 1990-11-28 1999-07-05 興和株式会社 Ｃｐｂ―ｉの安定化方法及び製剤組成物
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
JP2907603B2 (ja) * 1991-09-09 1999-06-21 雪印乳業株式会社 新規生理活性ペプチド、該活性ペプチドを有効成分とする胃酸分泌抑制剤、抗潰瘍剤及び飲食品
US6270757B1 (en) 1994-04-21 2001-08-07 Genetics Institute, Inc. Formulations for IL-11
US6372716B1 (en) 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
US5580856A (en) 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5707678A (en) 1995-04-12 1998-01-13 Galagen Inc. Method for microfiltration of milk or colostral whey
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
DK2275119T3 (da) * 1995-07-27 2013-11-11 Genentech Inc Stabil, isotonisk lyofiliseret proteinformulering
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
DE19543737A1 (de) 1995-11-24 1997-05-28 Hoechst Ag Verfahren zur Ultrafiltration von Peptide oder Proteine enthaltender biologischer Matrices
US5770700A (en) 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations
KR100236393B1 (ko) 1996-02-02 1999-12-15 나까니시 히로유끼 사람성장호르몬을 함유하는 의약제제
TWI240627B (en) 1996-04-26 2005-10-01 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
GB9610992D0 (en) * 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
DK1500329T3 (da) 1996-12-03 2012-07-09 Amgen Fremont Inc Humane antistoffer, der specifikt binder TNF-alfa
US5994511A (en) 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
US6172213B1 (en) 1997-07-02 2001-01-09 Genentech, Inc. Anti-IgE antibodies and method of improving polypeptides
KR20010030665A (ko) 1997-09-22 2001-04-16 세프라겐 코포레이션 유장 단백질의 순차적 분리법 및 그의 제제
RU2140287C1 (ru) * 1998-08-25 1999-10-27 Государственное унитарное предприятие "Иммунопрепарат" Способ получения альбумина
AU6405899A (en) 1998-10-26 2000-05-15 Galagen, Inc. Soy and immunoglobulin compositions
JP2000247903A (ja) 1999-03-01 2000-09-12 Chugai Pharmaceut Co Ltd 長期安定化製剤
UY26236A1 (es) 1999-07-07 2000-10-31 New Zeland Co Operative Dairy Metodos para obtener aislados de proteina y concentrados de calostro
DE60031999T2 (de) 1999-10-04 2007-06-06 Novartis Vaccines and Diagnostics, Inc., Emeryville Stabilisierte flüssige polypeptid-haltige pharmazeutische zusammensetzungen
ES2477996T3 (es) * 2000-08-11 2014-07-18 Chugai Seiyaku Kabushiki Kaisha Preparaciones estabilizadas que contienen un anticuerpo
ATE442862T2 (de) * 2000-10-12 2009-10-15 Genentech Inc Niederviskose konzentrierte proteinformulierungen
ES2184594B1 (es) 2001-01-17 2004-01-01 Probitas Pharma Sa Procedimiento para la produccion de gammaglobulina g humana inactivada de virus.
EP1409018B1 (en) 2001-07-25 2010-01-06 Facet Biotech Corporation Stable lyophilized pharmaceutical formulation the igg antibody daclizumab
CN1292655C (zh) 2001-11-08 2007-01-03 蛋白质设计实验室股份有限公司 IgG抗体稳定的液态药物制剂
ES2351786T3 (es) * 2001-11-13 2011-02-10 Genentech, Inc. Formulaciones con ligando apo2/trail y usos de las mismas.
WO2003072060A2 (en) 2002-02-27 2003-09-04 Immunex Corporation Polypeptide formulation
EP1551875A4 (en) * 2002-06-21 2006-06-28 Biogen Idec Inc TAMPON PREPARATIONS FOR CONCENTRATING ANTIBODIES AND METHODS FOR USE THEREOF
WO2004042012A2 (en) * 2002-11-01 2004-05-21 Bayer Healthcare Llc Process for concentration of macromolecules
GB0229444D0 (en) 2002-12-18 2003-01-22 Royal Free Hampstead Nhs Trust Diagnostic method and assay kit
RU2005129745A (ru) * 2003-02-24 2006-03-20 Джитиси Байотерапьютикс, Инк. (Us) Способы и устройство проточной фильтрации вдоль потока
RU2332986C2 (ru) 2003-04-04 2008-09-10 Дженентек, Инк. Высококонцентрированные композиции антител и белков
BRPI0507298A (pt) 2004-01-30 2007-07-03 Suomen Punainen Risti Veripalv processo para a produção de imunoglobulina segura a vìrus
US20080247991A1 (en) 2004-02-26 2008-10-09 Trout Bernhardt L Solution Additives For the Attenuation of Protein Aggregation
EP1780830A1 (en) 2004-08-19 2007-05-02 Electronic Navigation Research Institute, an Independent Administrative Institution Device using dielectric lens
US20060051347A1 (en) 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
JP6044754B2 (ja) 2012-01-19 2016-12-14 株式会社ジェイテクト クラッチプレートおよびその製造方法
WO2019035815A1 (en) 2017-08-16 2019-02-21 O&M Halyard International Unlimited Company METHOD AND SYSTEM FOR FASTENING ATTACHES IN A METHOD FOR MANUFACTURING FACIAL MASKS

Also Published As

Publication number Publication date
EP2292636A2 (en) 2011-03-09
PE20060816A1 (es) 2006-09-02
DK3805248T3 (da) 2023-04-03
MX342788B (es) 2016-10-12
KR101528970B9 (ko) 2022-12-09
US20230074486A1 (en) 2023-03-09
US20070237762A1 (en) 2007-10-11
EP4108259B1 (en) 2024-01-03
PT2292636T (pt) 2024-01-09
US20210095050A1 (en) 2021-04-01
PT4108259T (pt) 2024-03-07
EP4104859B1 (en) 2024-04-17
AU2005285243C1 (en) 2012-10-25
SI1786830T1 (sl) 2015-03-31
US12371510B2 (en) 2025-07-29
DK3805248T5 (da) 2023-04-24
ZA200701626B (en) 2008-10-29
JP2008512473A (ja) 2008-04-24
WO2006031560A2 (en) 2006-03-23
EP4104859A1 (en) 2022-12-21
ES2528541T3 (es) 2015-02-10
EP2292636B9 (en) 2024-01-03
PL4104859T3 (pl) 2024-08-26
CN104961797A (zh) 2015-10-07
KR20070109975A (ko) 2007-11-15
SI2292636T1 (sl) 2024-02-29
MY162525A (en) 2017-06-15
NZ553239A (en) 2009-11-27
KR20120135530A (ko) 2012-12-14
HK1101249A1 (en) 2007-10-12
CA2577317C (en) 2016-04-26
PL4108259T3 (pl) 2024-05-13
EP1786830A2 (en) 2007-05-23
BRPI0515649B8 (pt) 2021-11-03
HUE067662T2 (hu) 2024-11-28
WO2006031560A3 (en) 2006-08-24
MA28991B1 (fr) 2007-11-01
KR101528970B1 (ko) 2015-06-15
ES2968070T3 (es) 2024-05-07
ES2975166T3 (es) 2024-07-03
US20090214522A1 (en) 2009-08-27
DK2292636T3 (da) 2024-01-15
EP2292636A3 (en) 2013-05-01
US11767370B2 (en) 2023-09-26
EP3805248B1 (en) 2023-01-18
IL181372A0 (en) 2007-07-04
MY150549A (en) 2014-01-30
AR050641A1 (es) 2006-11-08
US20140370003A1 (en) 2014-12-18
JP5210633B2 (ja) 2013-06-12
CN102911268A (zh) 2013-02-06
SI4108259T1 (sl) 2024-04-30
EP4108259A1 (en) 2022-12-28
CN101056885B (zh) 2015-08-26
FI3805248T3 (fi) 2023-04-21
HK1215869A1 (zh) 2016-09-23
CA2577317A1 (en) 2006-03-23
US20060051347A1 (en) 2006-03-09
BRPI0515649B1 (pt) 2021-10-13
CN104961797B (zh) 2020-12-25
IL216851A0 (en) 2012-01-31
EP2292636B1 (en) 2023-10-18
PT4104859T (pt) 2024-07-02
JP2012097086A (ja) 2012-05-24
FI4108259T3 (fi) 2024-09-10
EP3805248A3 (en) 2021-07-14
RU2390524C2 (ru) 2010-05-27
DK1786830T3 (en) 2015-01-19
BRPI0515649A (pt) 2008-07-29
PT1786830E (pt) 2015-02-05
EP3805248A2 (en) 2021-04-14
GT200500254A (es) 2006-08-02
PL2292636T3 (pl) 2024-03-11
MX2007002812A (es) 2007-05-16
SG177161A1 (en) 2012-01-30
LT4104859T (lt) 2024-07-10
LT2292636T (lt) 2024-01-10
RU2007110534A (ru) 2008-10-20
PT3805248T (pt) 2023-04-05
FI4104859T3 (fi) 2024-07-16
ES2942574T3 (es) 2023-06-02
DK4104859T3 (da) 2024-07-08
HUE061899T2 (hu) 2023-08-28
EP1786830B1 (en) 2014-11-12
HUE065025T2 (hu) 2024-04-28
DK4108259T3 (da) 2024-03-11
FI2292636T3 (fi) 2024-01-12
ECSP077282A (es) 2007-03-29
PL3805248T3 (pl) 2023-05-22
SI4104859T1 (sl) 2024-08-30
SI3805248T1 (sl) 2023-05-31
AU2005285243A1 (en) 2006-03-23
NO333660B1 (no) 2013-08-05
ES2983099T3 (es) 2024-10-22
IL181372A (en) 2012-01-31
LT4108259T (lt) 2024-04-10
AU2005285243B2 (en) 2012-03-08
US10370456B2 (en) 2019-08-06
NO20071432L (no) 2007-03-16
HUE067296T2 (hu) 2024-10-28
TW200612989A (en) 2006-05-01
CN101056885A (zh) 2007-10-17
LT3805248T (lt) 2023-04-25
JP5426641B2 (ja) 2014-02-26
TWI372630B (en) 2012-09-21
PL1786830T3 (pl) 2015-05-29

Similar Documents

Publication Publication Date Title
TNSN07069A1 (en) Process for concentration of antibodies and therapeutic products thereof
IL195338A (en) An antibody comprising an FC variant containing amino acid replaces d or e at position 239, a medicament containing it and its use
WO2005063820A3 (en) Il-7 fusion proteins
MX348154B (es) Anticuerpos de enlace a il-1-beta y fragmentos de los mismos.
PL366826A1 (en) Reducing the immunogenicity of fusion proteins
AU2003215188A8 (en) Fusion proteins of humanized g250 specific antibodies and uses thereof
WO2004065417A3 (en) Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
SI1629011T1 (sl) Humane molekule za vezavo anti hu cd
WO2012054929A3 (en) Use of human serum albumin to decrease antigenicity of therapeutic proteins
EA200700917A1 (ru) Способ рефолдинга рекомбинантных антител
ATE376591T1 (de) Neisseria meningitidis antigene und zusammenstellungen
WO2007064917A3 (en) Methods of preparation of recombinant forms of human beta-amyloid protein and uses of these proteins
MY206284A (en) Anti-cd63 antibodies, conjugates, and uses thereof
IL172854A0 (en) Autologous self-tolerance inducing cells of monocytic origin and their use in pharmaceutical preparations
MX2009007572A (es) Proteinas de fusion que contienen los antigenos de rechazo de tumor ny-eso-1 y.
NO20072473L (no) Fremgangsmate for fremstilling av kinolinforbindelser og oppnadde produkter
WO2003074004A3 (en) Method of producing antigens
ATE408631T1 (de) Chimäres protein welches eine intramolekulare chaperon-ähnliche sequenz enthält und dessen anwendung zur insulinproduktion
WO2007093848A3 (en) Crystalline enoyl-(acyl-carrier-protein) reductase from heliobacter pylori
JOP20050124B1 (ar) عملية تركيز الاجسام المضادة والمنتجات العلاجية منها
EP1964847A3 (en) Method and apparatus for continuous large-scale radiolabeling of proteins
ATE466874T1 (de) Mit scytovirin der domäne 1 verwandte polypeptide
WO2001004143A3 (en) Prostase vaccine
CY1115969T1 (el) Διαδικασια για συμπυκνωση αντισωματων και θεραπευτικων προϊοντων αυτων
WO2005092922A3 (de) Antigen des pm-2 antikörpers und dessen verwendung